Cutaneous and systemic manifestations of EGFR inhibitor therapy: A case of PRIDE syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40547759.
- Also identified by DOI 10.4103/jfmpc.jfmpc_1928_24 and PMC identifier 12178502.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
EGFR inhibitors have revolutionized the treatment of advanced malignancies by targeting cancer cells specifically. The "PRIDE" complex encompasses a range of cutaneous adverse effects linked to EGFR inhibition therapy, including acneiform eruptions, xerosis, eczema, paronychia, and hair and nail changes. Cutaneous toxicities are among the most reported adverse events in this context. This report presents a case illustrating the dermatological side effects of EGFR inhibition therapy. The case involves a 73-year-old man with colon cancer undergoing (folinic acid, fluorouracil, irinotecan) + cetuximab treatment, presenting with diffuse rash, severe xerosis, bilateral scleral congestion, hyperpigmentation, nail changes, abdomen and toe ulcers, and skin infections.